Benefit-Risk Balance for Medicinal Products: Report Summary from the Council for International Organizations of Medical Sciences (CIOMS) Working Group XII药物产品的获益-风险平衡:国际医学科学组织理事会(CIOMS)工作组XII报告摘要Clinical TherapeuticsIF3.62026-09-090OA
Improving Informed Consent for English and Spanish Speakers in Clinical TrialsTHERAPEUTIC INNOVATION & REGULATORY SCIENCEIF1.92025-10-010PRE
Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone massBONEIF3.62007-04-0152PREAI
Efficacy of duloxetine in the treatment of diverse women with stress urinary incontinenceOBSTETRICS AND GYNECOLOGYIF4.72006-04-010PREAI
Safety and adverse effects associated with raloxifene: Multiple outcomes of raloxifene evaluationOBSTETRICS AND GYNECOLOGYIF4.72004-10-01138PREAI
Comparison of fracture, cardiovascular event, and breast cancer rates at 3 years in postmenopausal women with osteoporosisJOURNAL OF THE AMERICAN GERIATRICS SOCIETYIF4.52004-08-1642PREAI
Prostaglandin F2α induces a rapid decline in progesterone production and steroidogenic acute regulatory protein expression in isolated rat corpus luteum without altering messenger ribonucleic acid expressionBIOLOGY OF REPRODUCTIONIF31999-09-0157OAAI
The role of p53 tumor suppressor gene and bcl-2 protooncogene in rat corpus luteum deathAMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGYIF8.41997-08-0111PREAI